20190718 – TRANSGENE PR MHRA TG6002
Author: alcyon
Last Patient Enrolled in the Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC)
20190527-PR-Last-patient-TG4010-1L-EN
Combined General Meeting of May 22, 2019
20190522-TG-AGM-2019-EN
Financial visibility extended to Q4 2020, including $10 million revenue from collaboration with AstraZeneca to be received in Q2 2019
20190513-Resultats-Q1-2019-EN-
Transgene receives FDA IND Clearance for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer
20190513 PR IND TG4050 EN
Availability of Preparatory Documents for the Combined General Meeting of May 22, 2019
20190509MISE A DISPO AG – US
Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IO(TM) based armed oncolytic immunotherapies
20190502 – TG-AZ agreement – ENG
Transgene Completes Safety and Tolerability Assessment of TG4001 in Combination with Avelumab in Phase 1b Part of Trial in HPV-Positive Cancer Patients
20181220-Phase-1-TG4001-EN
Transgene Announces Financial Calendar for 2019
20181217 Financial calendar 2019 EN
Transgene Announces Upcoming Investor Meetings
20181205-PR-Investors-Meeting-agenda-T1-2019.pdf